Xtl Biopharmaceuticals (XTLB) Income towards Parent Company (2009 - 2024)

Xtl Biopharmaceuticals (XTLB) has reported Income towards Parent Company for 16 consecutive years, with -$6.2 million the latest figure, recorded in Q4 2024.

• Quarterly Income towards Parent Company fell 366.92% year-over-year to -$6.2 million in Q4 2024, while the trailing twelve-month figure through Dec 2025 was $1.3 million (up 121.66% YoY) and the FY2025 annual result came in at -$6.2 million, changed 0.0% from the prior year.
• Income towards Parent Company retreated to -$6.2 million in Q4 2024 per XTLB's latest filing, from $2.0 million in the prior quarter.
• Over the last five years, Income towards Parent Company for XTLB reached as high as $2.0 million in Q3 2024 and fell as low as -$6.2 million in Q4 2024.
• A 5-year average of -$400474.1 and a median of -$221001.0 in 2022 frame the typical range for Income towards Parent Company.
• The largest YoY upside for Income towards Parent Company was 114999900.0% in 2021 against a maximum downside of 17299840.0% in 2021.
• Year by year, Income towards Parent Company stood at -$2.0 in 2020, then tumbled by 11250050.0% to -$225003.0 in 2021, then tumbled by 582.21% to -$1.5 million in 2022, then gained by 13.36% to -$1.3 million in 2023, then tumbled by 366.92% to -$6.2 million in 2024.
• According to Business Quant data, Income towards Parent Company over the past three periods registered -$6.2 million, $2.0 million, and -$704000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.